Development of pH-Sensitive β-Adrenergic Receptor Antagonists
ACS Pharmacology & Translational Science · 14.08.2026 · 9 (8) · 2291-2303
DOI: 10.1021/acsptsci.6c00296 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 04.08.2026. Verfasst von Tobias Braun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Straße 10, Erlangen 9…. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
G protein-coupled receptors (GPCRs) can trigger distinct signaling pathways depending on their localization. Because their appearance is not restricted, GPCRs can signal not only from the plasma membrane but also from internalized compartments. The pH of endosomes is significantly lower compared to the extracellular environment, and thus, location-biased ligands can be developed by carefully adjusting their physicochemical properties. This work describes the development of pH-sensitive β-adrenergic receptor antagonists with weak basicity, conferring enrichment in acidic compartments. Starting from FDA-approved β-blockers including bisoprolol, metoprolol, propranolol, and nebivolol, chemical synthesis, physicochemical studies, in vitro pharmacological investigations, and structure–activity relationship studies led to ligands with considerably higher potency at representative acidic pH values of 6 and 6.5 compared to a pH of 7.4, which is typical for ligand binding at the plasma membrane. Bis-fluorination in the beta position of nitrogen substituents was the most effective and led to pH-sensitive analogs of bisoprolol, metoprolol, and propranolol with 10- to 12-fold higher potencies at endosome-specific pH values. Because endosomal β-adrenergic receptors are suggested to be associated with heart hypertrophy and cardiac dysfunction, the newly developed ligands may serve as lead compounds for the development of powerful and safe cardioprotective drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Straße 10, Erlangen 91058, Germany.
- FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Str. 10, Erlangen 91058, Germany.
ORCID-Profile: Harald Hübner, Peter Gmeiner
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Braun, T., Pröll, T., Weißing, N., Hübner, H., & Gmeiner, P. (2026). Development of pH-Sensitive β-Adrenergic Receptor Antagonists. ACS Pharmacology & Translational Science, 9(8), 2291-2303. https://doi.org/10.1021/acsptsci.6c00296
Vancouver
Braun T, Pröll T, Weißing N, Hübner H, Gmeiner P. Development of pH-Sensitive β-Adrenergic Receptor Antagonists. ACS Pharmacology & Translational Science. 2026;9(8):2291-2303. doi:10.1021/acsptsci.6c00296
BibTeX
@article{Braun2026,
author = {Braun, Tobias and Pröll, Theresa and Weißing, Nils and Hübner, Harald and Gmeiner, Peter},
title = {Development of pH-Sensitive β-Adrenergic Receptor Antagonists},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
volume = {9},
number = {8},
pages = {2291--2303},
doi = {10.1021/acsptsci.6c00296}
}
EUVIMED